

Ruth Pettengell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2369933/publications.pdf>

Version: 2024-02-01

56
papers

6,042
citations

257101

24
h-index

168136

53
g-index

57
all docs

57
docs citations

57
times ranked

8695
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the management of mature T&and natural killer&cell lymphomas (excluding cutaneous) Tj ETQq1 196, 507-522.	1.2	12
2	Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID&19: disease control as an important factor relative to recent chemotherapy or anti&CD20 therapy. British Journal of Haematology, 2022, 196, 892-901.	1.2	23
3	Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12-year follow-up of the EBMT lymphoma working party Lym1 trial. Bone Marrow Transplantation, 2021, 56, 1413-1421.	1.3	9
4	Integrated safety analysis of umbralisib, a dual PI3K&/CK1& inhibitor, in relapsed/refractory lymphoid malignancies. Blood Advances, 2021, 5, 5332-5343.	2.5	13
5	Avenue - Avelumab in the Frontline Treatment of Advanced Classic Hodgkin Lymphoma - a Window Study. Blood, 2021, 138, 2470-2470.	0.6	0
6	Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B&cell non&Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306). British Journal of Haematology, 2020, 188, 240-248.	1.2	17
7	Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3&5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial. Annals of Oncology, 2020, 31, 1251-1259.	0.6	41
8	COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncology, The, 2020, 21, 1309-1316.	5.1	473
9	COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet, The, 2020, 395, 1919-1926.	6.3	908
10	Favourable outcomes for high&risk Burkitt lymphoma patients (IPI 3&5) treated with rituximab plus CODOX&M/IVAC: Results of a phase 2 UK NCRI trial. EJHaem, 2020, 1, 133-141.	0.4	5
11	Safety Profile of Idelalisib in Patients with Refractory Follicular Lymphoma: Interim Analysis of a Noninterventional Study. Blood, 2020, 136, 48-50.	0.6	0
12	Lymphoma survivors&TM experience of participation in a home-based intervention post-chemotherapy. Quality of Life Research, 2019, 28, 2951-2955.	1.5	7
13	EXPLORATORY BIOMARKER ANALYSIS IN THE PH 3 ECHELON-1 STUDY: WORSE OUTCOME WITH ABVD IN PATIENTS WITH ELEVATED BASELINE LEVELS OF SCD30 AND TARC. Hematological Oncology, 2019, 37, 290-291.	0.8	1
14	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet, The, 2019, 393, 229-240.	6.3	517
15	Long-Term Response and Remission with Pixantrone in Patients with Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma: Post-Hoc Analysis of the Multicenter, Open-Label, Randomized PIX301 Trial. Clinical Drug Investigation, 2018, 38, 527-533.	1.1	13
16	Results of a multicentre <sc>UK</sc>&wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma. British Journal of Haematology, 2018, 181, 555-559.	1.2	13
17	Resolution of Peripheral Neuropathy (PN) in Patients Who Received A+AVD or ABVD in the Phase 3 ECHELON-1 Trial. Blood, 2018, 132, 2921-2921.	0.6	2
18	Results of a Phase 3 Randomised Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma Not Eligible for Stem Cell Transplantation. Blood, 2018, 132, 4189-4189.	0.6	4

#	ARTICLE	IF	CITATIONS
19	DURABLE BENEFIT OF RITUXIMAB MAINTENANCE POST-AUTOGRAFT IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA: 12-YEAR FOLLOW-UP OF THE EBMT LYMPHOMA WORKING PARTY LYM1 TRIAL. <i>Hematological Oncology</i> , 2017, 35, 32-33.	0.8	4
20	Rituximab maintenance improves overall survival of patients with follicular lymphoma—Individual patient data meta-analysis. <i>European Journal of Cancer</i> , 2017, 76, 216-225.	1.3	50
21	The Cost-effectiveness of Pixantrone for Third/Fourth-line Treatment of Aggressive Non-Hodgkinâ€™s Lymphoma. <i>Clinical Therapeutics</i> , 2016, 38, 503-515.	1.1	9
22	Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive Bâ€™cell nonâ€™Hodgkin lymphoma: postâ€™hoc analyses from a phase III trial. <i>British Journal of Haematology</i> , 2016, 174, 692-699.	1.2	26
23	Pixantroneâ€™ rituximab versus gemcitabineâ€™ rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma. <i>Future Oncology</i> , 2016, 12, 1759-1768.	1.1	16
24	Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor. <i>Supportive Care in Cancer</i> , 2016, 24, 2677-2684.	1.0	6
25	Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 67-76.	1.1	61
26	Therapeutic options in relapsed or refractory peripheral T-cell lymphoma. <i>Cancer Treatment Reviews</i> , 2014, 40, 1080-1088.	3.4	58
27	External validation of a risk model of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 2426-2432.	0.6	7
28	Rituximab Purging and/or Maintenance in Patients Undergoing Autologous Transplantation for Relapsed Follicular Lymphoma: A Prospective Randomized Trial From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2013, 31, 1624-1630.	0.8	111
29	Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. <i>Lancet Oncology</i> , The, 2012, 13, 696-706.	5.1	109
30	Economic costs of chemotherapy-induced febrile neutropenia among patients with non-Hodgkinâ€™s lymphoma in European and Australian clinical practice. <i>BMC Cancer</i> , 2012, 12, 362.	1.1	10
31	Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma. <i>Supportive Care in Cancer</i> , 2012, 20, 647-652.	1.0	51
32	Anemia and erythropoiesis-stimulating agent administration in patients with non-Hodgkin lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisoloneâ€™ rituximab chemotherapy: results from an observational study. <i>Leukemia and Lymphoma</i> , 2011, 52, 796-803.	0.6	10
33	2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. <i>European Journal of Cancer</i> , 2011, 47, 8-32.	1.3	895
34	CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. <i>Lancet Oncology</i> , The, 2011, 12, 1013-1022.	5.1	633
35	Guidelines for the management of mature Tâ€™cell and NKâ€™cell neoplasms (excluding cutaneous Tâ€™cell) Tj ETQq1 1.0.784314 rgBT /Dv	1.2	103
36	Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: An Updated Systematic Review and Meta-analysis of Randomized Trials. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1799-1806.	3.0	131

#	ARTICLE	IF	CITATIONS
37	Randomized Comparison of the Stanford V Regimen and ABVD in the Treatment of Advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. <i>Journal of Clinical Oncology</i> , 2009, 27, 5390-5396.	0.8	164
38	Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. <i>British Journal of Haematology</i> , 2009, 144, 677-685.	1.2	89
39	Implications of the European Organisation for Research And Treatment Of Cancer (EORTC) Guidelines on the Use of Granulocyte Colony-Stimulating Factor (G-CSF) for Lymphoma Care. <i>Clinical Drug Investigation</i> , 2009, 29, 491-513.	1.1	10
40	Advanced-Stage Follicular Lymphoma in the Rituximab Era. <i>Drugs</i> , 2009, 69, 1727-1737.	4.9	1
41	Febrile Neutropenia Risk Assessment and Granulocyte-Colony Stimulating Factor Support in Patients with Diffuse Large B Cell Lymphoma Receiving R-CHOP Regimens.. <i>Blood</i> , 2009, 114, 107-107.	0.6	3
42	Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy. <i>Annals of Hematology</i> , 2008, 87, 429-430.	0.8	79
43	Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. <i>Supportive Care in Cancer</i> , 2008, 16, 1299-1309.	1.0	122
44	The impact of follicular lymphoma on health-related quality of life. <i>Annals of Oncology</i> , 2008, 19, 570-576.	0.6	70
45	Radioimmunotherapy (RIT) in non-Hodgkin lymphoma. <i>Targeted Oncology</i> , 2007, 2, 173-179.	1.7	1
46	EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. <i>European Journal of Cancer</i> , 2006, 42, 2433-2453.	1.3	515
47	Pegfilgrastim Provides Effective Primary Prophylaxis Against Febrile Neutropenia in Patients with NHL Undergoing Chemotherapy: Initial Results from an Integrated Analysis - The Neulasta Versus Current Neutropenia Management Practice (Neucup) Project.. <i>Blood</i> , 2006, 108, 1150-1150.	0.6	1
48	Dose-limiting effects of neutropenic events in six European audits of adjuvant breast cancer chemotherapy. <i>Journal of Clinical Oncology</i> , 2004, 22, 619-619.	0.8	8
49	Dose-limiting effects of neutropenic events in six European audits of adjuvant breast cancer chemotherapy. <i>Journal of Clinical Oncology</i> , 2004, 22, 619-619.	0.8	6
50	Position paper on the therapeutic use of rituximab in CD20-positive diffuse large B-cell non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2003, 121, 44-48.	1.2	32
51	Autologous stem cell transplantation in follicular non-Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 2002, 29, S1-S4.	1.3	10
52	Hematopoietic Stem Cells: Proliferation, Purification, and Clinical Applications. , 2002, , 133-159.		2
53	A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. <i>British Journal of Haematology</i> , 2000, 109, 81-88.	1.2	101
54	High-dose therapy for aggressive non-Hodgkin's lymphoma. <i>British Journal of Hospital Medicine</i> , 1996, 56, 521-4.	0.0	0

#	ARTICLE	IF	CITATIONS
55	Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. <i>Blood</i> , 1992, 80, 1430-1436.	0.6	384
56	Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. <i>Blood</i> , 1992, 80, 1430-6.	0.6	95